Sodium phenylacetate/sodium benzoate

Drug Profile

Sodium phenylacetate/sodium benzoate

Alternative Names: AMMONUL; Sodium benzoate/sodium phenylacetate

Latest Information Update: 11 May 2015

Price : $50

At a glance

  • Originator Ucyclyd Pharma
  • Developer Hyperion Therapeutics; Ucyclyd Pharma
  • Class Benzoates; Hepatoprotectants; Neuroprotectants; Phenylacetates
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy; Hyperammonaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia
  • Discontinued Hepatic encephalopathy

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 May 2015 Hyperion Therapeutics has been acquired by Horizon Pharma
  • 12 Jun 2013 Ucyclyd exercises its option to retain sodium phenylacetate/sodium benzoate for Hyperammonaemia in patients with urea cycle disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top